効果的な臨床イノベーション

Krishna Vaddadi

Lancet (London, England)

|November 30, 2002

まとめ

No abstract available in PubMed .

関連する概念動画

こちらも読む

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え

Same author

Rehabilitation psychiatry: moving forward.

International review of psychiatry (Abingdon, England)·2010

Same author

Are we using excessive neuroleptics? An argument for systematic neuroleptic dose reduction in stable patients with schizophrenia with specific reference to clozapine.

International review of psychiatry (Abingdon, England)·2010

Same author

Essential fatty acids and mental illness.

International review of psychiatry (Abingdon, England)·2006

Same author

Tardive dyskinesia and essential fatty acids.

International review of psychiatry (Abingdon, England)·2006

Same journal

Rethinking anticoagulation intensity during extracorporeal membrane oxygenation.

Lancet (London, England)·2026

Same journal

Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial.

Lancet (London, England)·2026

Same journal

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Lancet (London, England)·2026

Same journal

Documenting hospice care.

Lancet (London, England)·2026

Same journal

After the wood chipper.

Lancet (London, England)·2026

Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026

関連する実験動画

効果的な臨床イノベーション

関連する概念動画

Rehabilitation psychiatry: moving forward.

Are we using excessive neuroleptics? An argument for systematic neuroleptic dose reduction in stable patients with schizophrenia with specific reference to clozapine.

Essential fatty acids and mental illness.

Tardive dyskinesia and essential fatty acids.

Rethinking anticoagulation intensity during extracorporeal membrane oxygenation.

Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial.

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Documenting hospice care.

After the wood chipper.

Assisted dying and the silencing of medicine's next generation.

関連する実験動画

効果的な臨床イノベーション

関連する概念動画

Rehabilitation psychiatry: moving forward.

Are we using excessive neuroleptics? An argument for systematic neuroleptic dose reduction in stable patients with schizophrenia with specific reference to clozapine.

Essential fatty acids and mental illness.

Tardive dyskinesia and essential fatty acids.

Rethinking anticoagulation intensity during extracorporeal membrane oxygenation.

Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial.

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Documenting hospice care.

After the wood chipper.

Assisted dying and the silencing of medicine's next generation.

関連する実験動画

効果的な臨床イノベーション

関連する概念動画

関連記事

Rehabilitation psychiatry: moving forward.

Are we using excessive neuroleptics? An argument for systematic neuroleptic dose reduction in stable patients with schizophrenia with specific reference to clozapine.

Essential fatty acids and mental illness.

Tardive dyskinesia and essential fatty acids.

Rethinking anticoagulation intensity during extracorporeal membrane oxygenation.

Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial.

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Documenting hospice care.

After the wood chipper.

Assisted dying and the silencing of medicine's next generation.

関連する実験動画

効果的な臨床イノベーション

関連する概念動画

関連記事

Rehabilitation psychiatry: moving forward.

Are we using excessive neuroleptics? An argument for systematic neuroleptic dose reduction in stable patients with schizophrenia with specific reference to clozapine.

Essential fatty acids and mental illness.

Tardive dyskinesia and essential fatty acids.

Rethinking anticoagulation intensity during extracorporeal membrane oxygenation.

Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial.

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Documenting hospice care.

After the wood chipper.

Assisted dying and the silencing of medicine's next generation.